EP1351573A4 - Procedes relatifs a la modulation de la croissance tumorale et de la metastase - Google Patents

Procedes relatifs a la modulation de la croissance tumorale et de la metastase

Info

Publication number
EP1351573A4
EP1351573A4 EP01994435A EP01994435A EP1351573A4 EP 1351573 A4 EP1351573 A4 EP 1351573A4 EP 01994435 A EP01994435 A EP 01994435A EP 01994435 A EP01994435 A EP 01994435A EP 1351573 A4 EP1351573 A4 EP 1351573A4
Authority
EP
European Patent Office
Prior art keywords
metastasis
methods
tumor growth
modulating tumor
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01994435A
Other languages
German (de)
English (en)
Other versions
EP1351573A1 (fr
Inventor
Francis Y Lee
Ronald Peck
David Chaplin
Ronald Pero
Klaus Edvardsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Oxi Gene Inc
Original Assignee
Bristol Myers Squibb Co
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Oxi Gene Inc filed Critical Bristol Myers Squibb Co
Publication of EP1351573A1 publication Critical patent/EP1351573A1/fr
Publication of EP1351573A4 publication Critical patent/EP1351573A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EP01994435A 2000-12-22 2001-12-20 Procedes relatifs a la modulation de la croissance tumorale et de la metastase Withdrawn EP1351573A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25819500P 2000-12-22 2000-12-22
US258195P 2000-12-22
PCT/US2001/050261 WO2002056692A1 (fr) 2000-12-22 2001-12-20 Procedes relatifs a la modulation de la croissance tumorale et de la metastase

Publications (2)

Publication Number Publication Date
EP1351573A1 EP1351573A1 (fr) 2003-10-15
EP1351573A4 true EP1351573A4 (fr) 2007-03-28

Family

ID=22979500

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01994435A Withdrawn EP1351573A4 (fr) 2000-12-22 2001-12-20 Procedes relatifs a la modulation de la croissance tumorale et de la metastase

Country Status (5)

Country Link
EP (1) EP1351573A4 (fr)
JP (2) JP2004523517A (fr)
AU (1) AU2002246827B2 (fr)
CA (1) CA2432792C (fr)
WO (1) WO2002056692A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE328599T1 (de) 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
EP1333820A2 (fr) 2000-10-27 2003-08-13 Aventis Pharma S.A. Combinaison de camptothecine et d'un derive de stilbene pour le traitement du cancer
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
JP2004523517A (ja) * 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
US20060205771A1 (en) * 2002-09-25 2006-09-14 Mark Noble Caspase inhibitors as anticancer agents
WO2004032947A1 (fr) * 2002-10-09 2004-04-22 Unibioscreen S.A. Extrait ayant un action antitumoral et antitoxique
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2047858A1 (fr) * 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Produits de combinaison pour le traitement contre le cancer
US20090192098A1 (en) 2007-11-21 2009-07-30 Oxigene, Inc. Method for treating hematopoietic neoplasms
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
EP3337495A4 (fr) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. Utilisation de vda pour améliorer des thérapies d'immunomodulation contre des tumeurs
CN107773556B (zh) * 2016-08-26 2020-08-18 广州安好医药科技有限公司 一种具有抗肿瘤药物功效的联合用药物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048591A1 (fr) * 1999-02-16 2000-08-24 Angiogene Pharmaceuticals Ltd. Combinaisons pour traiter les maladies faisant intervenir l'angiogenese

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (fr) 1987-01-06 1996-10-15 George R. Pettit Isolation, caracterisation structurelle et synthese de nouvelles substances antineoplastiques, appelees "combretastatines"
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
JP2002500227A (ja) 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ コンブレタスタチンａ−４プロドラッグとそのトランス異性体
JP2002537262A (ja) 1999-02-18 2002-11-05 オキシジェン，インコーポレイティド 血管破壊のターゲッティングに使用するための組成物および方法
JP2004523517A (ja) * 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000048591A1 (fr) * 1999-02-16 2000-08-24 Angiogene Pharmaceuticals Ltd. Combinaisons pour traiter les maladies faisant intervenir l'angiogenese

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHAPLIN D J ET AL: "ANTI-VASCULAR APPROACHES TO SOLID TUMOUR THERAPY: EVALUATION OF COMBRETASTATIN A4 PHOSPHATE", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 19, no. 1A, January 1999 (1999-01-01), pages 189 - 196, XP008013078, ISSN: 0250-7005 *
HORSMAN M R ET AL: "COMBRETASTATINS NOVEL VASCULAR TARGETING DRUGS FOR IMPROVING ANTI-CANCER THERAPY COMBRETASTATINS AND CONVENTIONAL THERAPY", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 476, 2000, pages 311 - 323, XP008013085, ISSN: 0065-2598 *
LINGYUN LI, B.S. AND OTHERS: "Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS, vol. 42, no. 4, 1998, pages 899 - 903, XP002419739 *
NELKIN B D ET AL: "COMBRETASTATIN A-4 AND DOXORUBICIN COMBINATION TREATMENT IF EFFECTIVE IN A PRECLINICAL MODEL OF HUMAN MEDULLARY THYROID CARCINOMA", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 8, no. 1, January 2001 (2001-01-01), pages 157 - 160, XP008013083, ISSN: 1021-335X *
See also references of WO02056692A1 *

Also Published As

Publication number Publication date
AU2002246827B2 (en) 2008-02-21
CA2432792A1 (fr) 2002-07-25
JP2009102350A (ja) 2009-05-14
CA2432792C (fr) 2012-04-03
WO2002056692A1 (fr) 2002-07-25
EP1351573A1 (fr) 2003-10-15
JP2004523517A (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
AU5091201A (en) Vegf-modulated genes and methods employing them
HK1067907A1 (en) Amplifier modulation
HK1055287A1 (en) Ferrite material
GB0008264D0 (en) Novel method and compounds
EP1351573A4 (fr) Procedes relatifs a la modulation de la croissance tumorale et de la metastase
SG99955A1 (en) Artificial stone and formation therefor
IL152116A0 (en) Prion-binding ligands and methods of using same
EP1313477A4 (fr) Composes et procedes
IL158750A0 (en) Reagents and methods for modulating dkk-mediated interactions
EP1274424A4 (fr) Composes et procedes
AU2140402A (en) Human elongase genes uses thereof and compounds for modulating same
EP1267800A4 (fr) M thodes permettant de moduler la croissance capillaire
AU2001278338A1 (en) Methods and compositions for modulating tumor growth
ZA200206318B (en) Modulation of bone formation.
AU2002364610A8 (en) Methods and materials for modulating trpc4
AU2002364612A8 (en) Methods and materials for modulating enac-beta
AU6174301A (en) Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activity
GB0022617D0 (en) Recording material and method
AU2002211359A1 (en) Stem cell-based methods for preventing and treating tumor
AU6975001A (en) Metalloprotease peptide substrates and methods
EP1343796A4 (fr) Composes et procedes
EP1287362A4 (fr) Compositions et methodes destinees a la modulation de l'expression specifique des tumeurs
AU2635001A (en) Polynucleotides for inhibiting metastasis and tumor cell growth
AU3402001A (en) Novel ligands and methods for preparing same
AU4949901A (en) Methods for inhibiting angiogenesis and tumor growth

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101AFI20070214BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070222

17Q First examination report despatched

Effective date: 20071219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130702